Progesterone

Social media will tell you birth control causes mental health issues, weight gain and infertility – here are the facts

Retrieved on: 
Tuesday, April 9, 2024
Research, Depression, Health, Friends, Faculty, Birth, Infertility, Intrauterine device, Menstrual cycle, Depo, Weight gain, Patient, IUD, Birth control, Social media, Mental health, Fertility, Medroxyprogesterone acetate, Life, Quarterlife, Adolescence, Systematic review, Woman, Progesterone, Family

Some women are reportedly even stopping their birth control as a result of misleading posts they’ve seen on TikTok and Instagram.

Key Points: 
  • Some women are reportedly even stopping their birth control as a result of misleading posts they’ve seen on TikTok and Instagram.
  • These three common misconceptions about birth control are cropping up online and need to be put in context:

1. Contraception causes depression

  • Countless videos on social media discuss the effect hormonal contraceptives have on mental health – with some creators claiming birth control causes mood changes and even depression.
  • Although there’s some correlation between mental health and some forms of contraception, there are many factors at play.
  • The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.
  • The evidence suggests depression is more common in adolescent girls – and diminishes after the first two years of taking these forms of birth control.
  • At present, there’s little conclusive evidence that contraception (both hormonal and non-hormonal types) cause mental health problems.

2. Contraception causes weight gain

  • Another common social media claim is that birth control causes weight gain.
  • There is one form of contraception that is linked to weight gain.
  • The Depo-Provera injection, which is administered every 12 weeks, has been proved to cause weight gain.


This weight gain may be due to the progesterone in the shot, which can cause people to feel hungrier – potentially leading to overeating and weight gain. If you’re concerned about potential weight gain, the injection is not the only form of contraception available. Other forms of hormonal and non-hormonal contraceptives have not been shown to affect your weight.

3. Birth control lowers your fertility

  • Another common claim on social media is that birth control causes fertility issues.
  • Research shows hormonal contraceptives have no affect on fertility.
  • Again, evidence shows that IUDs pose no risk to fertility.
  • A systematic review reports no specific differences in fertility between hormonal and non-hormonal IUDs.


Christopher O'Sullivan does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

As Opill Enhances Women's Reproductive Choices Dr. Mary Jane Minkin Highlights Key Differences Between the Progesterone-Only Opill and Traditional Estrogen-Based Contraceptives “The Pill”

Retrieved on: 
Monday, March 11, 2024
Health, FDA, Consumer, Women, Baby, Maternity, General Health, Pharmaceutical, Mother, Birth, Education, OBGYN, Combined oral contraceptive pill, Condom, Risk, Diabetes, Ovulation, Stroke, History, Sale, News, Fertility, Splenic infarction, Smoke, Perrigo, Woman, OTC, Pill, Cancer, Breast cancer, Safety, Progesterone, MUST, Migraine, Birth control

Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.

Key Points: 
  • Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.
  • "Education is key at this juncture to prevent an increase in unintended pregnancies in the coming months.
  • The Opill, significantly differs from the traditional birth control pill in that it is less effective at preventing ovulation when pills are missed or skipped for any reason.
  • The availability of the Opill OTC, or progesterone-only pill, is wonderful news for those women unable to take estrogen or 'The Pill.'

Knight Therapeutics Announces Launch of Bijuva® in Canada

Retrieved on: 
Tuesday, February 6, 2024
VMS, GUD, Uterus, Estradiol, Pan-American, Progesterone, Patient, Hot, TSX, Therapy, Capsule, Menopause, Hormone, Woman

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada.

Key Points: 
  • MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada.
  • VMS affects 60% to 80% of women entering menopause1 and are commonly known as hot flashes or flushes and night sweats.
  • Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to BIJUVA®.
  • Under the terms of the license agreement related BIJUVA® in Canada, Knight will pay TherapeuticsMD sales milestone fees and royalties based upon certain aggregate annual sales of BIJUVA® in Canada.

Evie, the First Women-Focused Health Ring, Takes 'Smart' to a New Level

Retrieved on: 
Monday, January 8, 2024
Walking, Daily, Woman, Progesterone, Heart rate, IOS, Research, FDA, Data analysis, Gold, Health, Apple, Evie, Android, Menstrual cycle, Sleep, CES, Finger, Life, Medical device

LAS VEGAS, Jan. 8, 2024 /PRNewswire/ -- The Evie Ring from Movano Health (Nasdaq: MOVE), the market's first women-focused smart ring, is redefining the wearable category with a unique band design, female-specific data interpretation, and AI-based trend analysis that goes beyond raw activity scores to improve users' ability to understand and manage their health. Evie earned a 2024 CES Innovation Honoree Award, begins shipping this month, and was showcased over the weekend at CES Unveiled in Las Vegas.

Key Points: 
  • Evie earned a 2024 CES Innovation Honoree Award, begins shipping this month, and was showcased over the weekend at CES Unveiled in Las Vegas.
  • Additionally, Evie's charging case is portable and can recharge the ring up to 10 times on one charge for easy on-the-go use.
  • The Evie Ring costs $269 with no subscription fees, keeping costs low over the life of the wearable.
  • "Add the focus on the nuances of women's physiology, and it's truly a game changer in the wearable space."

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Marketing, Artery, Pregnancy, Estetrol, INN, Pearl, Risk, Progesterone, Woman, IIA, ATC, Bleeding, International, Headache, Ageing, Language, Mouth, Tablet, Dysmenorrhea, Acne, Birth control, European Medicines Agency, Blister, Menstrual cycle, Pearl Index, Select, Birth, Patient, Vein, Safety, Cancer, Checklist, Anatomy, Vaginal bleeding, Internal bleeding, Ovulation

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Marketing, Artery, Pregnancy, Coronary thrombosis, Estetrol, INN, Risk, Pearl, Progesterone, Woman, IIA, ATC, Health system, Bleeding, International, Headache, Ageing, Language, VTE, Mouth, Tablet, Dysmenorrhea, Acne, Birth control, European Medicines Agency, Blister, Menstrual cycle, Pearl Index, Select, Birth, Patient, Vein, Safety, Cancer, Checklist, Anatomy, Vaginal bleeding, Internal bleeding, Ovulation

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research

Retrieved on: 
Friday, December 8, 2023
Research, Women, Genetics, Health, Consumer, Pharmaceutical, General Health, Science, Oncology, BRCA1, Perception, Woman, WHI, Prevalence, City, Incidence, Menopause, Risk, Breast cancer, Cardiovascular disease, Cancer, Patient, Multimedia, History, Hispanic, INSPIRE, Hysterectomy, Genetic testing, Data collection, BRCA2, Hormone replacement therapy, Prognosis, Standard of care, Ovarian cancer, Diagnosis, African Americans, Uterus, Progesterone, BRCA, Physician, Mutation, Medical imaging, Birth control, Hope

City of Hope, one of the largest cancer research and treatment organizations in the United States, will present innovative research at this year’s San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 5 to 9 in San Antonio, Texas.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, will present innovative research at this year’s San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 5 to 9 in San Antonio, Texas.
  • (Photo: Business Wire)
    Each year, about 10,000 physicians, scientists and other health care professionals attend the annual conference, which examines new breast cancer research and helps guide treatment of patients nationwide.
  • It is the largest and most prestigious scientific gathering on breast cancer research.
  • Women who have BRCA1 tend to have more aggressive breast cancers and the mutation can also cause ovarian cancer.

OOVA Launches Perimenopause Hormone Kit, First-of-its-Kind Estrogen Biomarker and App with Real-Time Data Tracking

Retrieved on: 
Wednesday, December 6, 2023
Woman, Genetics, Fertility, LH, HIPPA, Patient, Algorithm, Machine learning, Hormone replacement therapy, Ovulation, Health, Luteinizing hormone, Blood, HRT, Progesterone, Biomarker, Physician, Menopause, E3G, Birth control, Pharmaceutical industry

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Oova, Inc., the leading women's health platform revolutionizing remote hormone monitoring, announced today the launch of its at-home Perimenopause Hormone Kit. The kit is complete with urine-based, multi-hormone biomarkers including estrogen (E3G) and an app with real-time data tracking. Unlike other options on the market, which rely on blood or FSH-only urine tests that only capture a moment in time, Oova users are able to measure their actual hormone fluctuations across a 15-day period throughout a single cycle and their progress month-over-month. This gives women and their physicians insights into their perimenopause journey.

Key Points: 
  • The kit is complete with urine-based, multi-hormone biomarkers including estrogen (E3G) and an app with real-time data tracking.
  • Insights include measuring perimenopausal hormone activity, tracking unique physical symptoms, indicating fertility and confirming ovulation for those trying to conceive during perimenopause.
  • With the Perimenopause Hormone Kit, women can better understand their bodies, while tracking data that empowers them to make informed decisions with their physicians."
  • Also available is The Oova Perimenopause Membership Kit ($129.99/month) for an ongoing test strip subscription with full-circle support from Oova's hormone specialists and access to the Oova community.

Evie, the Smart Ring for Women from Movano Health, Available for Order Today

Retrieved on: 
Monday, November 20, 2023
Sleep, Woman, Research, Menstrual cycle, Gold, Heart rate, Ovulation, Health, Skin temperature, Silver, EST, Progesterone, Biomarker, Oxygen saturation (medicine), Medical device, Evie

PLEASANTON, Calif., Nov. 20, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) begins taking orders for the Evie Ring, the smart ring designed specifically for women, today at 12 pm EST. An innovative and comfortable form factor, a focus on helping women track and analyze their health and fitness, and an emphasis on big-picture data interpretation rather than individual activity scores set Evie apart from other wearables, providing a valuable new tool for women seeking to take control of their health.

Key Points: 
  • PLEASANTON, Calif., Nov. 20, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) begins taking orders for the Evie Ring , the smart ring designed specifically for women, today at 12 pm EST.
  • These core functions are integrated into a smart ring and companion app that break new ground in the wearable space.
  • Additionally, Evie comes with a portable charging case that holds 10+ ring charges so users can charge their ring from anywhere and at any time.
  • The Evie Ring is available exclusively through www.eviering.com in gold, rose gold, and silver finishes and in sizes 5-12 with a complimentary sizing kit for those who don't know their ring size.

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, November 9, 2023
Cream, Female, FDA, Bacterial vaginosis, Research, Human development, Trial of the century, Cooperative research and development agreement, Vaginal discharge, Food, Hot, Organon, Human services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, G&A, Progesterone, Phase 3, Quarter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Call, Development, NICHD, Webcast, Clinical trial, ID, Tamoxifen, FSAD, Bacteria, Hormone, NIH, Woman, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Patient, Bangladesh Technical Education Board, Pharmaceutical industry, Birth control, Bayer, Conference

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.

Key Points: 
  • ET
    SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.
  • XACIATO™ provides a new therapeutic option for the millions of women suffering from bacterial vaginosis in the U.S.
  • Financial Highlights for the Quarter ended September 30, 2023
    Cash and cash equivalents: $13.8 million at September 30, 2023.
  • Daré will host a conference call and live webcast today, November 9, 2023, at 4:30 p.m. Eastern Time to review financial results for the quarter ended September 30, 2023 and to provide a company update.